OYST News and Press, Oyster Point Pharma Inc. From 10/18/21

ION Geophysical (NYSE:IO) +45% sees Q3 revenues more than doubling Q/Q Valneva SE (NASDAQ:VALN) +36% after topline results from late-stage VLA2001 COVID-19 trial Adamis Pharmaceuticals (NASDAQ:ADMP) +35% after FDA approves opioid overdose treatment ZIMHI MeiraGTx...

Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease - TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease ...

Oyster Point Pharma, Inc. (OYST) Q2 2021 Earnings Conference Call August 05, 2021 04:30 PM ET Company Participants Daniel Lochner - Chief Financial Officer Jeffrey Nau - President and Chief Executive Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Stacy Ku - Co...

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q2 2021 Earnings Call Aug 05, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q2 2021 Earnings Call Transcript...

Oyster Point Pharma (NASDAQ:OYST): Q2 GAAP EPS of -$0.85 in-line. As of June 30, 2021, cash and cash equivalents were $154.8 million, compared to $192.6 million as of December 31, 2020 Press release. For further details see: Oyster Point Pharma EPS in-line

PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 202 1 Initiated Hiring of U.S. Sales Representatives in July, with a Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4’21, if Approved by the FDA Exclusive License Agreeme...

Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients with dry eye disease in Greater China Oyster Point Pharma will receive a $17.5 million upfront payment and up to 0.75% of equity in Ji Xing Pharmaceuti...

PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

Oyster Point Pharma (NASDAQ:OYST) announces the appointment of Donald Santel as non-executive chairperson and a director of the company's board.  Santel, who served as Executive Chairman of Adicet Bio, will take over as chairperson from Ali Behbahani, who will st...

PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that ...